Amgen, MariTide and weight loss

Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) looks to get in
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering Maritime—that is,
Amgen begins late-stage trials for obesity therapy
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug
Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.
Fierce Biotech3h
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
Amgen (NasdaqGS:AMGN) Declares US$2 Dividend Per Share For Q2 2025
Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
Drugmaker Amgen to invest $200 million in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Amgen price target raised to $294 from $275 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $294 from $275 and keeps an Underperform rating on the shares. For the last several ...
7AMGN : Behind the Scenes of Amgen's Latest Options Trends
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance.